Watson, IBM’S Supercomputer is Now Programmed to Recommend Perispinally Administered Etanercept as an Alzheimer’s Disease Treatment
“Perispilally administered etanercept meets urgent medical needs now as an Alzheimer’s disease treatment, stroke treatment and traumatic brain injury treatment,” states Augusto Ramirez of Neurological Wellness Center.
(PRWEB) March 26, 2013
According to an article in the March 2013 edition of Atlantic magazine titled “The Robot Will See You Now”, http://www.theatlantic.com/magazine/archive/2013/03/the-robot-will-see-you-now/309216/, IBM´s super computer Watson has teamed up with Memorial Sloan/Kettering Hospital to make diagnosis and treatment recommendations. IBM Watson has been programmed with 600,000 pieces of medical evidence from over two million pages of medical text as well as the entire English version of Wikipedia all stored in 15 terabytes of RAM (15 trillion bytes of memory). This is roughly equivalent to the information contained on a bookshelf that is 19 miles long.
“Computer-driven, evidence-based advice like that provided by IBM´s Watson gives validity to the off label use of prescription drugs” states Rolando Rodriguez, M.D., Neurosurgeon at Neurological Wellness Center. “The perispinal administration of the drug etanercept (Enbrel) to patients diagnosed with Alzheimer´s, stroke or traumatic brain injury (TBI) has the potential to enable a significant recovery in memory, mood, speech and physical function,” stated Dr. Rodriguez. “Doctors and nurses are drowning in information with new research popping up daily. They often don´t know what to do and are guessing as well as they can,” said Samuel Nussbaum, WellPoint´s Chief Medical Officer.
A general consensus is emerging among healthcare professionals that to effectively address the many problems in the present healthcare system in America will require a fundamental redesign, a transformation in which existing modalities are replaced by new care delivery paradigms. The expansion of computer medical decision support systems like that provided by IBM’s Watson has emerged as one of the areas where there is broad support among the medical community. The proliferation of biomedical information will continue to accelerate taxing the cognitive abilities of physicians as they struggle with the weight of new research findings, clinical guidelines, and recommendations of best practices. Computerized medical decision support systems certainly have the potential to produce better outcomes, increase productivity, lower costs and reduce the occurrence of adverse events.
Perispinal injections of the drug Enbrel are an excellent example. “The medical research is clear: a single injection has the potential to produce a life-changing recovery in persons afflicted with stroke or traumatic brain injury with little to no risk to health, yet the procedure is only slowly starting to gain traction with mainstream medicine”, states Dr. Rodriguez. IBM´s Watson has the potential to be a major game changer in the field of medicine. When physicians´ diagnoses and treatment decisions are evaluated with computer-assisted 20/20 hindsight WellPoint´s Samuel Nussbaum said that “health care professionals make accurate treatment decisions in lung cancer cases only 50% of the time”. “The dictates of a capitalistic healthcare system preclude a drug like Enbrel from ever gaining FDA approval for the treatment of stroke or TBI. The estimated cost for repurposing Enbrel for treating stroke and TBI is $100 million. Considering just one to eight doses are required for the complete treatment, I can be confident this drug will never be approved for stroke or TBI” said Augusto Ramirez, M.D., of Neurological Wellness Center. Neurological Wellness Center offers a complete two-hour course on Alzheimer’s treatment, stroke treatment and traumatic brain injury treatment covering all aspects of perispinal injection technique at their center in Managua Nicaragua.
For many, flying to Managua Nicaragua to receive this personalized training is an enormous expense and inconvenience. To overcome this problem, Neurological Wellness Center, under the direction of Augusto Ramirez, M.D., created Perispinal Enbrel Step-By-Step Instructional Video and accompanying e-book. This 24-minute video and 37-page e-book are now available online at http://www.neurological-recovery-guide.com.
Augusto Ramirez, M.D., Director of Neurological Wellness Center, a private medical group in Managua Nicaragua, authorized this press release.
Neurological Wellness Center´s perispinal Enbrel is profoundly effective as an Alzheimer´s treatment, stroke treatment and TBI treatment. The complete treatment recommendation: for stroke is one 25mg injection of Enbrel every four days for a total of four doses over 16 days; for TBI is one 25mg injection of Enbrel every four days for a total of eight doses. This compares with Amgen/Pfizer´s FDA-approved dose schedule for moderate plaque psoriasis of 50mg twice weekly for three months followed by 50mg weekly for life. The Neurological Wellness Center´s maximum recommended dose for Alzheimer´s disease is 25mg/week for life.
The drug Enbrel is available now. Enbrel received FDA approval in 1998. Its safety profile is well understood. For Enbrel to effectively treat Alzheimer´s, stroke and TBI, it must be administered to the back of the neck precisely between the cervical vertebrae C-5 and C-6. This perispinal injection allows Enbrel to enter the brain by lymph drainage assisted by gravity. Fortunately for the millions of people now afflicted with Alzheimer´s, stroke and TBI, a video is now available online detailing in step-by-step fashion how to administer a perispinal injection of Enbrel,” said Dr. Rolando Rodrigues.
To enroll in a hands-on instructional course on perispinal injections visit http://www.reversealzheimersnow.com.
To purchase an instructional video and e-book on administering perispinal injections visit: http://www.neurological-recovery-guide.com/
To purchase Enbrel at the lowest prices in North America visit: http://www.genuine-enbrel-cheaper.com.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2013/3/prweb10525602.htm